HeartBeam Granted Patent for 12-Lead Electrocardiogram Patch Monitor

The U.S. Patent and Trademark Office has issued a patent to HeartBeam Inc. for a 12-lead electrocardiogram (ECG) patch monitor designed to detect acute coronary syndrome (ACS) and cardiac arrhythmia. 

“This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” HeartBeam CEO and Founder Branislav Vajdic, Ph.D., said. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability.”

The newly issued patent (No. 11,419,538 B2) expands on the HeartBeam’s previously granted U.S. patent (No. 11,071,490 B1) for a 12-lead ECG patch monitor technology. The patch patent follows HeartBeam’s already granted core patents for remote detection of heart attacks. These two issued patch patents significantly increase HeartBeam’s intellectual property footprint, and they further widen the impact HeartBeam’s technology could have on cardiac patients and their physicians.
 
The global ECG patch monitor market, estimated to reach $4.8B by 2030, is currently limited to arrhythmia detection via the use of single-lead ECG devices. By elevating patch monitor technology with a synthesized 12-lead ECG, HeartBeam can help doctors better detect arrhythmia and diagnose both myocardial infarction (heart attack) and angina.
 
“The ECG monitors available today are primarily used for detection of abnormal heart rhythms associated with atrial fibrillation or syncope,” said Martin Burke, D.O., FACC, cardiac electrophysiologist and chief scientific officer of the CorVita Science Foundation, which holds The Rory Childers Electrocardiology Research Center and Fellowship program. “A 12-lead ECG patch would provide additional information to aid in diagnosing conditions such as ACS or more specific arrhythmias that current single-lead patches cannot accurately detect.”
 
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration.